Methotrexate use in systemic lupus erythematosus

Abstract

Low dose pulse oral methotrexate (MTX) is a well established treatment for rheumatoid arthritis, and short term open studies have suggested beneficial effects of MTX in SLE. This study was designed to investigate MTX treatment maintenance rates in SLE using life table analysis, and to determine whether MTX use was associated with a dose reduction of concomitant steroid therapy.

All SLE patients managed by physicians affiliated with a single centre were studied cross- sectionally. Information regarding disease variables and drug use were ascertained by interview and chart review. Drug therapy data including dates of treatment and indications for treatment were analysed using Kaplan-Keier life table methods.

Among 101 subjects with SLE, 25 MTX treatment episodes were observed in 24 subjects. The period studied totalled 19 766 patient-days, with a median (range) duration of observed MTX treatment of 14.4 (5.1-41.6) months. The median (range) initial and peak MTX doses with 7.5 (2.5- 10)mg/wk and 10 (7.5-15)mg/week respectively. The principal indication for commencing methotrexate therapy was arthritis. Only two subjects terminated treatment for toxicity, with the most common reason for termination being remission. The cumulative probability of continuing treatment was 68% at 12 months and 61 % at 24 months, or 75% and 71 % respectively if cessations for remission were excluded. The median (interquartile range) monthly steroid intake during MTX therapy [279.4 (193.4-492.9) mg] was somewhat lower than during the 6 months prior to [298.1 (237.9-531.4)428.8) mg] MTX therapy, but this difference was not significant. A total of 36% of subjects reduced their steroid dose during MTX therapy, but this reduction was not significant.

Treatment of SLE with MTX, predominantly for arthritis, was well tolerated over prolonged periods of observation. Toxicity of sufficient severity to lead to treatment termination was uncommon. A subset of subjects were able to reduce steroid intake during MTX therapy, but no overall reduction in steroid dose was observed.

Keywords

Methotrexate systemic lupus erythematosus drug treatment

References

Austin HA et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.

Schnabel A. , Gross WL Low dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Sem Arthritis Rheum 1994; 23: 310-327.

Morand EF , McCloud PM , Littlejohn GO Life table analysis of 879 treatment episodes with slow-acting anti-rheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-708.

Wolfe F. , Hawley DJ , Cathey MA Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.

Williams HJ et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1985; 28: 721-730.

Weinblatt ME et al. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 129-137.

Andersen PA et al. Weekly pulse methotrexate in rheumatoid arthritis. Ann Rheum Dis 1985; 103: 489-496.

Kremer JM , Phelps CT Long term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992 ; 35: 138-145.

Fiechtner JJ , Miller DR , Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with felty's syndrome. Arthritis Rheum 1989; 32: 194-201.

10.

Espinoza LR et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872-877.

11.

Sneller MC et al. An analysis of forty-two wegener' granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-613.

12.

Van Den Hoogen Fhj et al. Low dose methotrexate treatment in systemic sclerosis (letter). J Rheumatol 1991 ; 18: 1763-1764.

13.

Davidson JR , Graziano FM , Rothenberg RJ Methotrexate therapy for systemic lupus erythematosus (letter). Arthritis Rheum 1987; 30: 1195-1196.

14.

Rothenberg RJ et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988; 31: 612-615.

15.

Wilke WS et al. Methotrexate for systemic lupus erythematosus: A retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991; 9: 581-587.

16.

Abud-Medoza C. , Sturbaum AK , Vazquez-Compean R, Gonzalez-Amaro. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993; 20: 731-733.

17.

Walz LeBlanc BAE, Dagenais P, Urowitz MB, Gladman DD. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 836-838.

18.

Wilson K. , Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus . J Rheumatol 1994; 21: 1674-1677.

19.

Hawley DJ , Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: Analysis of 122 studies. J Rheumatol 1991; 18: 1008-1014.

20.

Morand EF , McCloud PI , Littlejohn GO Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992; 51: 1318-1321.

21.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

22.

Gladman D. et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J Rheumatol 1992; 19: 1820-1821.

23.

Jolivet J. et al. The pharmacology and clinical use of methotrexate. N Eng J Med 1983; 309: 1094-1114.

24.

Olsen NJ , Callahan LF , Diucas T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate . Arthritis Rheum 1987; 30: 481-488.

25.

Olsen NJ , Murray LM Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378-385.

26.

Chang DM , Bapiste P. , Schur PH The effect of antirheumatic drugs on interleukin 1 activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 1990; 17: 1148-1157.

27.

Barrera P. et al. Circulating soluble tumour necrosis factor receptors, interleukin-2 receptors, tumour necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy . Arthritis Rheum 1993; 36:

28.

Segal R. , Dayan N. , Zinger H. , Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus; clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995; 101: 66-72;

29.

Weinblatt ME et al. Arthritis Rheum 1988 ; 31: 167-175;

30.

Miescher PA , Riethmuller D. Diagnosis and treatment of systemic lupus erythematosus. Sem Haematol 1965; 2: 1-28.

31.

Dubois EL Management of discoid and systemic lupus erythematosus, Lupus Erythematosus . In: Dubois EL (ed). A review of the Current Status of Discoid and Systemic Lupus Erythematosus and Their Variants. 2nd end. University of Southern California Press: Los Angeles, 1974; pp 537-612.